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Introduction
• Depressive disorders among the most common
mental disorders that are commonly reported  
in adults (Kessler et al., 2012)
• Current antidepressants can lead to “emotional
blunting,” impairing the ability to identify  
feelings.
• Antidepressant use reduces positive affect and
emotional awareness (Kajanoja et al.,
2018).
• Alternatives involve the use of psilocybin to 
combat depression
Overview of Psilocybin
 Psilocybin, an indoleamine hallucinogen, is an 
agonist of the serotonin 5-HT2A receptor  
(Vollenweider, et al., 1998)
 Produces symptoms similar to individuals  
who experience psychosis (Vollenweider, et  
al., 1998)
 Produces a potent dream-like state and
distortions in space and time perception  
(Brown et al., 2017)
 Serotonin 5-HT2A receptor has been known  
to play a role in depression (Eison &  Mullins,
1995)
 Relaxation of high-level beliefs  (Carhart-
Harris, 2019)
Psilocybin may reduce
depression
and can lead to
personality changes.
Scan the QR code to  
download the full paper.
Psilocybin and Depression
Ross et al. (2016) study involving 29 patients  
with cancer-related depression and anxiety
 Single dose of psilocybin (0.3 mg/kg) or  
niacin along with psychotherapy.
 Decreased anxiety and depression in  
cancer patients after dose
Carhart-Harris et al. (2016) study involving 12  
patients with treatment-resistant depression
 Reduced depression and anxiety after 3  
months
Figure 1. Psilocybe semilanceata
Psilocybin and Personality
Roseman et. al (2018) examined changes in  
personality measures with psilocybin therapy in  
patients with clinical depression
 Significant decrease in Neuroticism and  
trend-level increases in Conscientiousness
 Significant increases in Openness and  
Extraversion
 Study suggests that greater insightfulness  
occurred after treatment
Discussion
 Most studies involving psilocybin have rather  
small sample sizes
 Legality of psilocybin may hinder psilocybin  
research
 No adverse effects
 No control group within some of these studies
 Possible cofound within studies due to  
addition of psychotherapy which may explain  
reduction in depression
 Further research with better experimental  
designs should be conducted to assess efficacy  
of psilocybin
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